SEC Form 4 · accession 0001209191-16-157033
ANTARES PHARMA, INC. · ATRS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert F Apple
Officer — President & CEO · Director
Period of report
Dec 27, 2016
Accepted (ET)
Dec 29, 2016 · 5:33 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001016169
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Dec 27, 2017 | M | 60,000 | $1.23 | A | 929,719 | D | |
| Common StockF1 | Dec 27, 2017 | F | 39,717 | $2.35 | D | 890,002 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.23 | Dec 27, 2016 | M | 60,000 | D | — | Jan 15, 2017 | Common Stock | 60,000 | 0 | D |
Explanation of responses
- F1Represents shares used for payment of the exercise price and tax liability for the underlying stock option.
- F2The options vested in equal quarterly installments over three years following the grant date of January 16, 2007.